Literature DB >> 21289155

Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

M A Pfaller1, L B Boyken, R J Hollis, J Kroeger, S A Messer, S Tendolkar, D J Diekema.   

Abstract

We performed 24- and 48-h MIC determinations of posaconazole and voriconazole against more than 16,000 clinical isolates of Candida species. By using the 24- and 48-h epidemiological cutoff values (ECVs), the categorical agreement between the 24-h and reference 48-h broth microdilution results ranged from 97.1% (C. parapsilosis and voriconazole) to 99.8% (C. krusei and voriconazole), with 0.0 to 2.9% very major discrepancies (VMD). The essential agreement (within 2 log(2) dilutions) between the 24- and 48-h results was 99.6% for both posaconazole and voriconazole. The MIC results obtained for both posaconazole and voriconazole after only 24 h of incubation may be used to determine the susceptibilities of Candida spp. to these important antifungal agents. The applications of ECVs to this large collection of Candida isolates suggests the potential to develop 24-h species-specific clinical breakpoints for both posaconazole and voriconazole.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289155      PMCID: PMC3122818          DOI: 10.1128/JCM.02437-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Has antifungal susceptibility testing come of age?

Authors:  John H Rex; Michael A Pfaller
Journal:  Clin Infect Dis       Date:  2002-09-24       Impact factor: 9.079

2.  European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.

Authors:  Gunnar Kahlmeter; Derek F J Brown; Fred W Goldstein; Alasdair P MacGowan; Johan W Mouton; Anders Osterlund; Arne Rodloff; Martin Steinbakk; Pavla Urbaskova; Alkiviadis Vatopoulos
Journal:  J Antimicrob Chemother       Date:  2003-07-01       Impact factor: 5.790

Review 3.  The role of antifungal susceptibility testing in the therapy of candidiasis.

Authors:  Duane R Hospenthal; Clinton K Murray; Michael G Rinaldi
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803

4.  Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia.

Authors:  John W Baddley; Mukesh Patel; Marga Jones; Gretchen Cloud; Anita C Smith; Stephen A Moser
Journal:  Diagn Microbiol Infect Dis       Date:  2004-10       Impact factor: 2.803

5.  Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients.

Authors:  Susan Hadley; José A Martinez; Laura McDermott; Barbara Rapino; David R Snydman
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

6.  Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.

Authors:  M A Pfaller; A Espinel-Ingroff; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-01-12       Impact factor: 5.948

7.  Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

Authors:  J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

9.  Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

10.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more
  10 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method.

Authors:  Shawn R Lockhart; Carol B Bolden; Naureen Iqbal; Randall J Kuykendall
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

3.  Impact of new antifungal breakpoints on antifungal resistance in Candida species.

Authors:  Annette W Fothergill; Deanna A Sutton; Dora I McCarthy; Nathan P Wiederhold
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

4.  Multidrug-resistant endemic clonal strain of Candida auris in India.

Authors:  A Chowdhary; V Anil Kumar; C Sharma; A Prakash; K Agarwal; R Babu; K R Dinesh; S Karim; S K Singh; F Hagen; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-20       Impact factor: 3.267

5.  Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.

Authors:  Shawn R Lockhart; Naureen Iqbal; Angela A Cleveland; Monica M Farley; Lee H Harrison; Carol B Bolden; Wendy Baughman; Betsy Stein; Rosemary Hollick; Benjamin J Park; Tom Chiller
Journal:  J Clin Microbiol       Date:  2012-08-08       Impact factor: 5.948

6.  Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method.

Authors:  Shallu Kathuria; Pradeep K Singh; Cheshta Sharma; Anupam Prakash; Aradhana Masih; Anil Kumar; Jacques F Meis; Anuradha Chowdhary
Journal:  J Clin Microbiol       Date:  2015-03-25       Impact factor: 5.948

7.  Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values.

Authors:  M C Arendrup; Anupam Prakash; Joseph Meletiadis; Cheshta Sharma; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

8.  Invasive mycosis due to species of Blastobotrys in immunocompromised patients with reduced susceptibility to antifungals.

Authors:  Anil Kumar; Rachana Babu; Swapna Bijulal; Mohan Abraham; P Sasidharan; Shallu Kathuria; Cheshta Sharma; Jacques F Meis; Anuradha Chowdhary
Journal:  J Clin Microbiol       Date:  2014-08-27       Impact factor: 5.948

9.  Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry.

Authors:  Narges Aslani; Ghasem Janbabaei; Mahdi Abastabar; Jacques F Meis; Mahasti Babaeian; Sadegh Khodavaisy; Teun Boekhout; Hamid Badali
Journal:  BMC Infect Dis       Date:  2018-01-08       Impact factor: 3.090

10.  Calcofluor white combination antifungal treatments for Trichophyton rubrum and Candida albicans.

Authors:  Joanne M Kingsbury; Joseph Heitman; Sheldon R Pinnell
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.